by The growing concerns over the health of both mother and newborn during pregnancy require accurate diagnosis and timely monitoring to optimize care outcomes. Preterm birth testing help identify high-risk pregnancies early through advanced screening and diagnosis of preterm labor. Preterm birth is one of the leading causes of infant death and disabilities worldwide. Preterm birth testing help doctors provide targeted interventions and necessary treatment to delay or prevent premature deliveries. These tests aid in analyzing vaginal fluids, cervical tissues or blood samples to detect early signs of preterm labor.
The global Preterm Birth And Prom Testing Market is estimated to be valued at US$ 1.69 Bn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The development of novel predictive biomarkers is one of the key trends in preterm birth and prom testing market. Researchers are discovering new biomarkers in cervical fluid, vaginal fluids or blood that can effectively predict the risk of preterm birth at an early stage of pregnancy. For instance, insulin-like growth factor binding protein-1 (IGFBP-1) assessed in vaginal fluids has shown promising results in preterm birth prediction. Similarly, placental alpha microglobulin-1 (PAMG-1) levels assessed through prom testing is being evaluated for its predictive potential. Such novel biomarkers can facilitate more targeted screening and clinical management of at-risk pregnancies. This represents an area of active research with the potential to revolutionize preterm birth prevention strategies.
Porter’s Analysis
Threat of new entrants: The preterm birth and prom testing market has moderate threat of new entrants due to high capital costs associated with R&D and manufacturing of testing kits and equipment required.
Bargaining power of buyers: Buyers in the form of hospitals, clinics and diagnostic centers have moderate bargaining power due to availability of substitute testing methods.
Bargaining power of suppliers: Suppliers of raw materials and components have low to moderate bargaining power as they operate in a competitive market.
Threat of new substitutes: Threat of new substitutes is moderate as new non-invasive testing methods can be developed as substitutes to current invasive methods.
Competitive rivalry: The market is highly competitive with major focus on new product innovations and geographic expansions.
Key Takeaways
The Global Preterm Birth And Prom Testing Market Size is expected to witness high growth. The global Preterm Birth And Prom Testing Market is estimated to be valued at US$ 1.69 Bn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030.
The North America region currently dominates the market owing to high awareness levels and supportive government initiatives for maternal and child care in the region. Factors such as rapid urbanization, increasing healthcare expenditure and rising focus on women healthcare are expected to boost market growth in the Asia Pacific region during the forecast period.
Key players operating in the preterm birth and prom testing market are Sanofi S.A., AbbVie Inc., Perrigo Company PLC, 3M, Lee’s Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals, Bausch Health, and Novartis International AG. Sanofi S.A. is a leading supplier of cervical cerclage devices while AbbVie Inc. and Glenmark Pharmaceuticals are some of the top players offering preventive drugs in the market. Key players are focusing on new product launches and geographical expansions to strengthen their market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
